{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:43:25Z","timestamp":1780325005531,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2019M3E5D1A02069615"],"award-info":[{"award-number":["NRF-2019M3E5D1A02069615"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2020R1C1C1005122"],"award-info":[{"award-number":["NRF-2020R1C1C1005122"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jocn.2021.06.021","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T13:37:47Z","timestamp":1624282667000},"page":"311-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders"],"prefix":"10.1016","volume":"90","author":[{"given":"Woochang","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2021.06.021_b0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"10.1016\/j.jocn.2021.06.021_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617722347","article-title":"Treatment strategies for autoimmune encephalitis","volume":"11","author":"Shin","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jocn.2021.06.021_b0015","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jocn.2021.06.021_b0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2013a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2021.06.021_b0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000073059","article-title":"Therapy with intravenous immunoglobulins: complications and side-effects","volume":"50","author":"Wittstock","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jocn.2021.06.021_b0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.06.021_b0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J Neurol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jocn.2021.06.021_b0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/cei.12551","article-title":"Intravenous immunoglobulin-related thromboembolic events - an accusation that proves the opposite","volume":"178","author":"Basta","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2021.06.021_b0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","article-title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","volume":"127","author":"Ammann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jocn.2021.06.021_b0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2021.06.021_b0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","article-title":"Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study","volume":"133","author":"Ram\u00edrez","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jocn.2021.06.021_b0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.24358","article-title":"Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs","volume":"91","author":"Ammann","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jocn.2021.06.021_b0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case-control study of thromboembolic events associated with IV immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2021.06.021_b0070","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0140-6736(92)90806-E","article-title":"Effect of high-dose intravenous immunoglobulin therapy on blood rheology","volume":"339","author":"Reinhart","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2021.06.021_b0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.46.1.250","article-title":"Reversible encephalopathy with cerebral vasospasm in a Guillain-Barr\u00e9 syndrome patient treated with intravenous immunoglobulin","volume":"46","author":"Voltz","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.06.021_b0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1423-0410.1998.7420074.x","article-title":"IVIG adverse reactions: potential role of cytokines and vasoactive substances","volume":"74","author":"Bagdasarian","year":"1998","journal-title":"Vox Sang"},{"key":"10.1016\/j.jocn.2021.06.021_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-9-1","article-title":"Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study","volume":"9","author":"Ramagopalan","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jocn.2021.06.021_b0090","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1177\/0271678X18799241","article-title":"Hypercapnia increases brain viscoelasticity","volume":"39","author":"Hetzer","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jocn.2021.06.021_b0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa1406761","article-title":"Clinical features and outcomes of takotsubo (stress) cardiomyopathy","volume":"373","author":"Templin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2021.06.021_b0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jns.2017.02.012","article-title":"Takotsubo cardiomyopathy in amyotrophic lateral sclerosis","volume":"375","author":"Choi","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2021.06.021_b0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijcard.2008.05.060","article-title":"Left ventricular thrombus formation and cardioembolic complications in patients with Takotsubo-like syndrome: a systematic review","volume":"131","author":"de Gregorio","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jocn.2021.06.021_b0110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jocn.2021.06.021_b0115","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","article-title":"The clinical features of 16 cases of stroke associated with administration of IVIg","volume":"60","author":"Caress","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.06.021_b0120","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.jocn.2021.06.021_b0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","article-title":"Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations","volume":"65","author":"Wolberg","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jocn.2021.06.021_b0130","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000008742","article-title":"Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821003167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821003167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:29:33Z","timestamp":1760822973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821003167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":26,"alternative-id":["S0967586821003167"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.06.021","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}